Manufacturing and extraction valuation

What is a cannabis manufacturing business actually selling?

A processor license can hold three different businesses, and each deserves its own valuation.

Revenue stream	What it is	How durable buyers consider it
Owned brand	Your own vapes, edibles, concentrates, or pre-rolls sold to retailers	Most durable if store-level sell-through is steady and not discount-driven
White-label or co-manufacturing	Making product sold under another company’s brand	Depends on contract term; the brand owner can move production
Toll processing	Extracting or converting a cultivator’s biomass for a fee or a split	Least durable unless under written minimum-volume contracts

Most processors run a mix. The first job in any valuation is to break revenue, gross margin, and customer concentration out by stream. A blended figure hides whether the earnings belong to the business or to one customer relationship.

Which product categories are growing?

Category direction changes what a buyer will pay for the same earnings. Headset’s retail data for the 12 months ending June 2026 covers $24.3 billion of sales across 16 state markets:

Category	Sales	Share	Year-over-year change
Flower	$9.60 billion	39.4%	down 0.7%
Vapor pens	$6.15 billion	25.3%	up 0.8%
Pre-rolls	$3.84 billion	15.8%	up 10.1%
Edibles	$2.91 billion	11.9%	up 0.3%
Concentrates	$1.23 billion	5.0%	down 7.7%
Beverages	$289 million	1.2%	up 7.8%

Headset also reports unit sales up 5.5% against dollar sales up 0.8%, which means prices fell. For a manufacturer, that is margin pressure unless input costs fell faster. Cheap biomass in oversupplied states has helped extractors on the input side; see how oversupply and price compression affect value. A processor weighted to dabbable concentrates is selling into a shrinking category. One weighted to pre-rolls or vapes is not. Buyers notice.

What do reported deals tell us?

Very little about multiples, which is itself useful to know. Most processor and brand deals disclose no price. When Wyld announced its acquisition of edibles maker Gron on 5 January 2026, combining brands sold in roughly 7,500 and 4,500 retail locations, it gave no financial terms.

One small deal with disclosed terms: LEEF Brands agreed on 16 April 2026 to acquire the parent of California vape brand Himalaya for 13,688,000 common shares plus warrants, total consideration of about US$2.5 million. No cash, and the target’s revenue was not disclosed, so no multiple can be computed. The lesson is structure. Brand acquisitions by small public companies are commonly paid in stock, which the seller must then hold or sell into a thin market. The trade-offs are on the page comparing cash, stock, and seller notes.

The only checkable multiple remains the public one: Viridian Capital’s November 2025 median of 5.1x enterprise value to 2026 EBITDA for larger multi-state operators. A single-state processor with concentrated customers should expect to price below that. Anyone quoting a precise private multiple for processors is quoting opinion, not data.

Illustrative: valuing the streams separately

Illustrative only. The multiples are placeholders that show how risk weighting works. They are not market quotes and this is not an appraisal.

A processor has $1,000,000 of normalized EBITDA. A blended 3.5x would give $3,500,000. Now split it:

Stream	EBITDA	Buyer’s view	Illustrative multiple	Value
Owned brand, 140 retail accounts, steady sell-through	$450,000	Durable	4.5x	$2,025,000
White-label, one client, 14 months left on contract	$350,000	At risk at renewal	2.5x	$875,000
Toll processing, month-to-month, three growers	$200,000	Could leave any month	1.5x	$300,000
Total	$1,000,000		3.2x blended	$3,200,000

The seller who extends the white-label contract to three years and signs the tolling clients to minimum volumes before going to market changes the middle column, and with it the price. That work costs little and is worth doing a year ahead. See preparing a cannabis business for sale.

How much are the equipment and build-out worth?

Extraction with flammable solvents requires a classified room, engineering review, and fire-code sign-off, covered on the page about extraction facility requirements. That approved room took time and money to create. To a buyer who will operate in place, it has real value, because it avoids the permitting delay. To anyone else it has almost none, because the room cannot be moved and a landlord may want it removed.

Equipment is similar. Installed and running, it supports the earnings and is valued through them. Counting it again on top of an earnings multiple is double counting. Equipment value matters separately in three cases:

1. Earnings are weak or negative, so the asset approach sets the floor.
2. The business owns substantial idle or excess equipment a buyer does not need.
3. Equipment is leased or financed, in which case the debt comes off the price. See equipment financing for cultivation and extraction.

Inventory, receivables, and working capital

Manufacturers carry more working capital than retailers. Three items get adjusted at closing:

• Inventory. Crude oil, distillate, and finished goods are priced at current wholesale, not at cost. Distillate bought or made a year ago may be worth less than book. Aging finished goods near expiry are excluded. See inventory and biomass at closing.
• Receivables. Retailers in stressed markets pay slowly. Buyers usually discount or exclude balances past 60 or 90 days, and some states regulate credit terms between licensees.
• Customer concentration. If one retail chain or distributor is a large share of sales, expect part of the price to move into an earn-out tied to keeping that account.

280E and the hemp line

Under 280E, production costs that are properly part of inventory still reduce taxable income, while selling and marketing costs do not. A toll processor is mostly production cost. A brand house spends heavily on sales and marketing. With equal EBITDA, the brand house serving adult-use markets pays more federal tax. Product made under a state medical license has been Schedule III since 28 April 2026, so the medical share of output matters. The per-license detail is on 280E by license type.

Some processors also make hemp-derived cannabinoid products. Public Law 119-37 narrows the federal definition of hemp. Most of that change now takes effect 11 December 2026 after H.R. 6500 was signed on 2 September 2026; cannabinoids the plant cannot naturally produce lose hemp status on 12 November 2026. Buyers will carve that revenue out and value it on its own, often at little or nothing until the rules settle. Background is on intoxicating hemp products: regulatory status.

What a buyer’s diligence list looks like

1. Revenue and gross margin by stream and by top ten customers, trailing 24 months.
2. Contracts for white-label and tolling work: term, minimums, exclusivity, change-of-control clauses.
3. Store-level sell-through for owned brands, where distributor or data-service reports exist.
4. Test failures, recalls, and any product holds; see how compliance history affects value.
5. Fire marshal approvals, engineering peer review, and the equipment list with serial numbers and liens.
6. Trademark filings at the state level and ownership of formulations and standard operating procedures.

The manufacturing and extraction license hub covers how these businesses are bought and sold, and the overview of valuation methods by license type shows where processors sit against other licenses. This page is educational. It is not an appraisal and is not tax or legal advice.